Protalix BioTherapeutics Sees Large Decline in Short Interest (PLX)
Protalix BioTherapeutics (NYSE:PLX) saw a large decline in short interest in the month of June. As of June 13th, there was short interest totalling 5,828,771 shares, a decline of 2.2% from the May 30th total of 5,962,058 shares, AR Network reports. Based on an average daily trading volume, of 117,374 shares, the short-interest ratio is currently 49.7 days. Currently, 8.0% of the company’s shares are sold short.
Several analysts have recently commented on the stock. Analysts at JPMorgan Chase & Co. cut their price target on shares of Protalix BioTherapeutics from $8.00 to $7.00 in a research note on Tuesday, May 13th. They now have an “overweight” rating on the stock. Separately, analysts at Jefferies Group reiterated a “hold” rating on shares of Protalix BioTherapeutics in a research note on Monday, May 12th. They now have a $4.25 price target on the stock, down previously from $5.50. Finally, analysts at Zacks downgraded shares of Protalix BioTherapeutics from a “neutral” rating to an “underperform” rating in a research note on Wednesday, April 9th. They now have a $4.30 price target on the stock.
Protalix BioTherapeutics (NYSE:PLX) opened at 3.80 on Wednesday. Protalix BioTherapeutics has a one year low of $3.70 and a one year high of $5.72. The stock’s 50-day moving average is $3.87 and its 200-day moving average is $4.31. The company’s market cap is $352.2 million.
Protalix BioTherapeutics (NYSE:PLX) last issued its quarterly earnings data on Thursday, May 22nd. The company reported ($0.08) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.07) by $0.01. Analysts expect that Protalix BioTherapeutics will post $-0.22 EPS for the current fiscal year.
Protalix BioTherapeutics, Inc is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins based on its ProCellEx protein expression system, ProCellEx.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.